ArticleAvicenna journal of phytomedicine
Article in Avicenna journal of phytomedicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The objective of this study was to assess the protective effects of Materials and Methods: Thirty-six male Wistar rats were divided into six groups (n=6/group) for 50 days. On day 51, the study assessed serum levels of luteinizing hormone (LH), follicle-stimulating hormone (FSH), and testosterone (TT), as well as antioxidant enzyme activity, nitric oxide levels, and various parameters related to testicular tissue (including the ferric reducing ability of plasma (FRAP), thiol, and thiobarbituric acid reactive substances (TBARS) levels). The stereological indices of seminiferous tubules were measured using serial sections of testicular tissue stained with hematoxylin and eosin, while the apoptosis rate of testicular parenchymal cells (p53, Caspase-3, and Bcl-2 positive cells) was also determined. Results: In the groups treated with HPE, particularly at 750 mg/kg, there was a significant increase (p<0.05) in LH, FSH, and TT hormone levels, an enhanced serum antioxidant enzyme activity and significantly reduced (p<0.05) nitric oxide levels. HPE inhibited the apoptotic pathway involving Bax/p53/Caspase-3 (significantly decreased (p<0.05) all three genes), thereby preserving the structure and function of the testicular tissue. Consequently, the number of p53 and Caspase-3 positive testicular cells decreased significantly (p<0.05), while the number of Bcl-2 positive cells increased. Conclusion: HPE demonstrated potential in protecting the function and structure of testis against toxic and oxidative damages.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.